The road to the front of line

[biopearl123]

Geron has always had a strategy. It’s very slow moving in case you haven’t noticed. Even though they may have a unique drug, they chose not to strike at the heart of the king directly. Instead by garnering second line approval which seems highly likely, their strategy appears to see what physician and patient experiences with the new drug can do to aid in drug choice and establishing a reputation for a drug that will likely prove superior and move to front line first choice treatment. It will take some time. Luspatercept , as CKTC has pointed out is in the “sweet spot” but pretty soon three questions will be asked of Imetelstat: 1. Will you live longer? 2Will you live better? 3. Will your risk of progression to HR or AML be slowed or abolished? Sooner or later there may be a head to head study to look at best first line treatment but not until Imetelstat proves itself in the second line position. People will be asking themselves if it should be used earlier in the disease. Disease modification is a big deal and can impact numbers 1,2,3 in a heartbeat.Don’t think Imetelstat will stay second line for long.

[kmall]

We've all heard about the tortoise winning the race.....but this has been one heck of a slog. Fingers crossed for March 14. -Kmall

[Ryan]

Well said, but…

Won’t be second in line for long … how do you define “long”??